Source: International Congress 2019 – Update on anticoagulant therapy: controversy and progress
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Cohen (London, United Kingdom). Direct - acting oral anticoagulants: which agent for which patient?. International Congress 2019 – Update on anticoagulant therapy: controversy and progress

Member's Comments

No comment yet.

Related content which might interest you: Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016 Investigating the steroids and long-acting β2-agonists combination: why do we need more? Source: Eur Respir J 2004; 23: 501-502 Year: 2004 Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 How effective are oral steroids in asthma action plans? Source: International Congress 2017 – Asthma management Year: 2017 Update on novel anticoagulants: indications, dosing alternatives and outcomes Source: International Congress 2018 – Pulmonary embolism: what we need to know Year: 2018 Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe? Source: Eur Respir J 2016; 48: 1230-1233 Year: 2016 Immunotherapy: when, who and which drug? Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer Year: 2018 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 How can we minimise the use of regular oral corticosteroids in asthma? Source: Eur Respir Rev, 29 (155) 190085; 10.1183/16000617.0085-2019 Year: 2020 Is there a problem with oral corticosteroid use in asthma? Source: Virtual Congress 2020 – Airway diseases Year: 2020 Anticoagulant treatment of venous thromboembolism: established and new oral agents, remaining questions Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism Year: 2014 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 New oral anticoagulants (NOACs) vs. warfarin: Are doctors ready to switch? Source: International Congress 2015 – New developments in medical education, web and internet Year: 2015 Systemic treatment: an adjuvant indication? Source: Annual Congress 2004 - Lung metastases Year: 2004 Antiviral drugs: which and when? Source: Annual Congress 2006 - Influenza: from avian flu to pandemia? Year: 2006 What is the role of oral corticosteroids in the era of biologics in asthma? Source: International Congress 2019 – State of the art session: Airway disease Year: 2019 Inhaled medication: which device for which patient? Source: Eur Respir Monogr 2015; 69: 213-223 Year: 2015 Late Breaking Abstract - Overuse of oral corticosteroids in asthma – modifiable factors and potential role of biologics Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021